, Partial reimbursement by the national healthcare system. 33: Girls only. 2-dose vaccination schedule. 34: Two doses. Females only, 3 doses. Recommended, but not mandatory, vol.32

. Pellegrino, , 2009.

, PRISMA Flow chart Table 32 presents the main characteristics of the 11 studies, Figure, vol.44, 2017.

D. Angelo, , 2014.

. Arnheim-dahlström, , 2012.

. Grimaldi-bensouda, , 2014.

. Miranda, 2008) retained for the meta-analysis: six were cohorts, 2013.

. Chao, 2017) and two were pooled analyses of randomised clinical trials, 2014.

. Verstraeten, , 1985.

;. Cependant and . Flahault, Bien que le virus ait pu être retrouvé dans la salive, les larmes, le lait maternel, la sueur et l'urine, aucune contamination ne semble possible via la nourriture ou l'eau, le partage des couverts, l'allaitement, les baisers, les poignées de main, incidence annuelle des infections par le virus de l'hépatite B était de 6, 1997.

. France, les déclarations obligatoires des cas incidents d'infection par le virus de l'hépatite B entre 2010 et 2014 ont montré que les trois modes de transmission les plus fréquents étaient les relation sexuelles (38,5%), les voyages dans les pays de haute endémicité (21,5%), et les procédures médicales invasives comme la dialyse, la chirurgie ou la transplantation (5,4%). (Nicand, 2016), 2018.

, Etant donnée la nature observationnelle des études identifiées, les auteurs ont souvent fourni plusieurs estimations du risque, rendant difficile le choix d'une seule mesure pour la méta-analyse. Il a donc été décidé de considérer trois estimations : brute, ajustée, et celle estimée pour une fenêtre de trois mois après la vaccination. L'hétérogénéité a été quantifiée et son origine déterminée en enlevant une après une, les études incluses. Des analyses en sous-groupe (enfants versus adultes

, Deux types d'événement ont été traités séparément : les premiers épisodes de SEP et les événements démyélinisants centraux

, Pour le troisième scénario, considérant une fenêtre de temps réduite à 3 mois après la vaccination, les valeurs étaient de, Dans le cas des estimations brutes, la méta-analyse a produit un odds ratio (OR) poolé de 1,19 [95%CI 0, vol.46, p.39

. Liu, En conclusion, bien que les OR convergent, en moyenne, vers une valeur de 1,2-1,3, aucune des estimations poolées plus, à l'inverse du virus HBV, les préservatifs ne semblent pas représenter un moyen de protection efficace, Les analyses en sous-groupe ont également abouti à des résultats non statistiquement significatifs, 2016.

, Pour les hommes ayant des rapports sexuels avec d'autres hommes, l'immunisation active est recommandée jusqu'à l'âge de 26 ans, selon un schéma d'administration à trois doses à 0, 2 et 6 mois, La vaccination est également recommandée pour certaines populations bien spécifiques, 2018.

. Andrews, Sur les 2863 références identifiées, onze articles ont été sélectionnés

D. Angelo, , 2014.

. Arnheim-dahlström, , 2012.

. Grimaldi-bensouda, , 2014.

. Miranda, Six concernaient des études de cohortes, deux étaient des études cas-témoins, 2008.

. Qian, l'une était une série de cas auto-contrôlés, 2017) et deux étaient des analyses poolées d'essais cliniques randomisés, 2014.

. Verstraeten, 2008) anti-HBV, non statistiquement significatifs, 2017.

D. Angelo, , 2014.

. Arnheim-dahlström, 2017) se distingue des autres du fait qu'elle rapporte une valeur "protectrice" d'odds ratio, La dernière étude, p.31, 2008.

D. Angelo, Six études se sont concentrées sur la problématique de l'association du vaccin anti-HPV avec la survenue de cas incidents de SEP, 2008.

, A nouveau, la méta-analyse de ces études n'a pas mis en évidence de lien entre la survenue de SEP et la vaccination anti-HPV avec un odds ratio de 0, p.98

, On ne dénombre que deux études ayant produit une estimation du risque de survenue d'un syndrome de Guillain et Barré dans les suites d'une vaccination anti-HBV, Les odds ratios publiés étaient

. Grimaldi-bensouda, , 2014.

M. Absoud, M. J. Lim, W. K. Chong, C. G. De-goede, K. Foster et al., Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features, Mult Scler, vol.19, issue.1, pp.76-86, 2013.
DOI : 10.1177/1352458512445944
URL : http://journals.sagepub.com/doi/pdf/10.1177/1352458512445944

S. Adler, J. Martinez, D. S. Williams, and J. G. Verbalis, Positive association between blood brain barrier disruption and osmotically-induced demyelination, Mult Scler, vol.6, issue.1, pp.24-31, 2000.
DOI : 10.1191/135245800678827419

C. Hoc, Utilisation des modèles expérimentaux dans l'investigation d'un lien de causalité potentiel entre vaccins anti-hépatite B et SEP Retrieved from, 2007.

A. Alvarez-requejo, A. Carvajal, B. Begaud, Y. Moride, T. Vega et al., , 1998.

, Estimate based on a spontaneous reporting scheme and a sentinel system, Eur J Clin Pharmacol, vol.54, issue.6, pp.483-488

M. J. Alvarez-soria, A. Hernandez-gonzalez, S. Carrasco-garcia-de-leon, M. A. Del-real-francia, M. J. Gallardo-alcaniz et al., Rev Neurol, vol.52, issue.8, pp.472-476, 2011.

N. Andrews, Epidemiological designs for vaccine safety assessment: methods and pitfalls, Biologicals, vol.40, issue.5, pp.389-392, 2012.
DOI : 10.1016/j.biologicals.2011.08.010

N. Andrews, J. Stowe, and E. Miller, No increased risk of Guillain-Barré syndrome after human papillomavirus vaccine: A self-controlled case-series study in England, Vaccine, vol.35, pp.1729-1732, 2017.

M. G. Angelo, M. P. David, J. Zima, L. Baril, G. Dubin et al., Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme, pharmacoepidemiology and drug safety, vol.23, issue.5, pp.466-479, 2014.

M. G. Angelo, J. Zima, F. Tavares-da-silva, L. Baril, and F. Arellano, Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience, pharmacoepidemiology and drug safety, vol.23, issue.5, pp.456-465, 2014.

D. Antona, L'hépatite B en France: aspects épidémiologiques et stratégie vaccinale, 2008.

L. Arnheim-dahlström, B. Pasternak, H. Svanström, P. Sparén, and A. Hviid, , 2013.

, Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study, bmj, vol.347, p.5906

D. Aron, Hepatitis B vaccination. Pleading for the vital principle of protection, vol.2, pp.361-369, 2002.

A. Ascherio, S. M. Zhang, M. A. Hernan, M. J. Olek, P. M. Coplan et al., Hepatitis B vaccination and the risk of multiple sclerosis, New England Journal of Medicine, vol.344, issue.5, pp.327-332, 2001.

C. Y. Bahk, M. Cumming, L. Paushter, L. C. Madoff, A. Thomson et al., Publicly Available Online Tool Facilitates Real-Time Monitoring Of Vaccine Conversations And Sentiments, Health Aff (Millwood), vol.35, issue.2, pp.341-347, 2016.
DOI : 10.1377/hlthaff.2015.1092

M. Balinska and C. Leon, Perceptions of hepatitis B vaccination in France. Analysis of three surveys. Revue d'epidemiologie et de sante publique, vol.54, pp.1-95, 2006.

R. Ball, N. Halsey, M. M. Braun, L. H. Moulton, A. D. Gale et al.,

M. E. Salive, Development of case definitions for acute encephalopathy, encephalitis, and multiple sclerosis reports to the vaccine: Adverse Event Reporting System, J Clin Epidemiol, vol.55, issue.8, pp.819-824, 2002.

H. Balshem, M. Helfand, H. J. Schünemann, A. D. Oxman, R. Kunz et al., GRADE guidelines: 3. Rating the quality of evidence, Journal of clinical epidemiology, vol.64, issue.4, pp.401-406, 2011.

B. Banwell, J. Kennedy, D. Sadovnick, D. L. Arnold, S. Magalhaes et al., Incidence of acquired demyelination of the CNS in Canadian children, Neurology, vol.72, issue.3, pp.232-239, 2009.

D. Baxby, R. Baxter, and N. P. Klein, Kaiser Permanente Vaccine Study Center: Highlights of, Vaccines (Basel), vol.318, issue.7180, pp.139-153, 1999.

R. Baxter, E. Lewis, B. Fireman, F. Destefano, J. Gee et al., Case-centered Analysis of Optic Neuritis After Vaccines, Clin Infect Dis, vol.63, issue.1, pp.79-81, 2016.

R. Baxter, E. Lewis, K. Goddard, B. Fireman, N. Bakshi et al.,

N. P. Klein, Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis, Clin Infect Dis, vol.63, issue.11, pp.1456-1462, 2016.

B. ;. Bégaud, L. John-wiley-&-sons, L. Belbasis, V. Bellou, E. Evangelou et al., Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and metaanalyses, Lancet Neurol, vol.14, issue.3, pp.263-273, 2000.

P. Benkimoun, Vaccination contre l'hépatite B: succès pour la santé publique dans le monde, pp.120-136, 2011.

I. Borget, L. Abramowitz, and P. Mathevet, Economic burden of HPV-related cancers in France, Vaccine, vol.29, issue.32, pp.5245-5249, 2011.

M. J. Bradburn, J. J. Deeks, J. A. Berlin, and A. Localio, Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events, Statistics in medicine, vol.26, issue.1, pp.53-77, 2007.

B. Brochet, J. De-sèze, C. Lebrun-frenay, H. Zéphir, and G. Defer, La sclérose en plaques-Clinique et thérapeutique, 2017.

C. Brouard, L. Leon, C. Pioche, V. Bousquet, C. Semaille et al., Hepatitis B and C screening in France in 2010. The LaboHep, Study. Bull Epidemiol Hebd, vol.19, pp.205-209, 2010.

P. Browne, D. Chandraratna, C. Angood, H. Tremlett, C. Baker et al., Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity, Neurology, vol.83, issue.11, pp.1022-1024, 2014.

T. M. Burns, Guillain-Barré syndrome, 2008.

J. A. Cabrera-gomez, N. Echazabal-santana, L. Garcia-gonzalez, A. M. Ramos-cedeno, M. O. Rodriguez-roque et al.,

L. Tellez, A severe episode in a patient with recurrent disseminated acute encephalitis due to vaccination against hepatitis B. For or against vaccination?, Rev Neurol, vol.34, issue.4, pp.358-363, 2002.

R. L. Cameron, S. Ahmed, and K. G. Pollock, Adverse event monitoring of the human papillomavirus vaccines in Scotland, Internal medicine journal, vol.46, issue.4, pp.452-457, 2016.

, Canadian National Vaccine Safety Network (CANVAS), 2018.

A. Cassini, E. Colzani, A. Pini, M. J. Mangen, D. Plass et al., Impact of infectious diseases on population health using incidencebased disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, Euro Surveill, issue.16, pp.17-00454, 2009.

, Human papillomavirus vaccination coverage among adolescent girls, Control of Infectious Diseases. MMWR Weekly, vol.48, pp.1129-1132, 1999.

, Leading causes of death and numbers of deaths, by sex, race, and Hispanic origin: United States, Vaccine Safety Datalink (VSD), 1980.

H. Chang, H. L. Lee, M. Yeo, J. S. Kim, D. I. Shin et al., Recurrent optic neuritis and neuromyelitis optica-IgG following first and second human papillomavirus vaccinations, Clin Neurol Neurosurg, vol.144, pp.126-128, 2016.
DOI : 10.1016/j.clineuro.2016.03.023

C. Chao, N. Klein, C. Velicer, L. Sy, J. Slezak et al., Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine, Journal of Internal Medicine, vol.271, issue.2, pp.193-203, 2012.

C. M. Chen, H. J. Chen, W. S. Chen, C. C. Lin, C. C. Hsu et al., Clinical effectiveness of influenza vaccination in patients with rheumatoid arthritis, Int J Rheum Dis, vol.21, issue.6, pp.1246-1253, 2018.

T. Chitnis, Pediatric multiple sclerosis, Neurologist, vol.12, issue.6, pp.299-310, 2006.

C. Cohen, A. Houdeau, and A. Khromava, Central Demyelinating Diseases After Vaccination Against Hepatitis B Virus: A Disproportionality Analysis Within the VAERS Database, Drug Saf, 2018.

J. P. Collet, N. Macdonald, N. Cashman, and R. Pless, Monitoring signals for vaccine safety: the assessment of individual adverse event reports by an expert advisory committee, Advisory Committee on Causality Assessment. Bull World Health Organ, vol.78, issue.2, pp.178-185, 2000.

C. Confavreux, S. Suissa, P. Saddier, V. Bourdes, and S. Vukusic, Vaccinations and the risk of relapse in multiple sclerosis, New England Journal of Medicine, vol.344, issue.5, pp.319-326, 2001.

, Definition and Application of Terms for Vaccine Pharmacovigilance: Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance, 2012.

N. W. Crawford, A. Mcminn, J. Royle, T. Lazzaro, M. Danchin et al., Recurrence risk of a hypotonic hyporesponsive episode in two Australian specialist immunisation clinics, Vaccine, vol.36, issue.41, pp.6152-6157, 2018.

A. Creange, G. Temam, and J. P. Lefaucheur, Lumbosacral acute demyelinating polyneuropathy following hepatitis B vaccination, Autoimmunity, vol.30, issue.3, pp.143-146, 1999.

J. D'alembert and . De-mechanique, Opuscules Mathematiques: Ou Memoires Sur Differens Sujets De Geometrie, 1761.

C. Danavaro, , 2014.

C. De-martel, M. Plummer, J. Vignat, and S. Franceschi, Worldwide burden of cancer attributable to HPV by site, country and HPV type, Int J Cancer, vol.141, issue.4, pp.664-670, 2017.

R. De-vincenzo, C. Conte, C. Ricci, G. Scambia, and G. Capelli, Long-term efficacy and safety of human papillomavirus vaccination, Int J Womens Health, vol.6, pp.999-1010, 2014.

V. Demicheli, A. Rivetti, C. D. Pietrantonj, C. Clements, and T. Jefferson, Hepatitis B vaccination and multiple sclerosis: evidence from a systematic review, Journal of viral hepatitis, vol.10, issue.5, pp.343-344, 2003.
DOI : 10.1046/j.1365-2893.2003.00423.x

F. Denis, Hepatitis B vaccination: evolution of hepatitis B vaccine coverage; public health impact, efficiency limits, New vaccines, Bull Acad Natl Med, vol.200, issue.1, pp.33-45, 2016.

F. Denis, A. Goudeau, and A. Aufrere, , 1998.

, Bull Soc Pathol Exot, vol.91, issue.1, pp.37-40

T. Derrough, K. Olsson, V. Gianfredi, F. Simondon, H. Heijbel et al., Immunisation Information Systems -useful tools for monitoring vaccination programmes in EU/EEA countries, Euro Surveill, issue.17, p.22, 2016.
DOI : 10.2807/1560-7917.es.2017.22.17.30519
URL : https://www.eurosurveillance.org/deliver/fulltext/eurosurveillance/22/17/eurosurv-22-30519-3.pdf?itemId=/content/10.2807/1560-7917.ES.2017.22.17.30519&mimeType=pdf&containerItemId=content/eurosurveillance

R. Dersimonian and N. Laird, Meta-analysis in clinical trials, Control Clin Trials, vol.7, issue.3, pp.177-188, 1986.

F. Destefano, T. Verstraeten, L. A. Jackson, C. A. Okoro, P. Benson et al.,

, Vaccinations and risk of central nervous system demyelinating diseases in adults, Archives of Neurology, vol.60, issue.4, pp.504-509, 2003.

F. J. Dimario, . Jr, M. Hajjar, and T. Ciesielski, A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus, J Child Neurol, vol.25, issue.3, pp.321-327, 2010.

G. Direction and . Transmissibles, , 2004.

M. M. Eftekharian, M. Mousavi, M. B. Hormoz, G. Roshanaei, and M. Mazdeh, Multiple sclerosis and immunological-related risk factors: Results from a case-control study, Human antibodies, vol.23, issue.1, pp.31-36, 2014.

H. El-adssi, M. Debouverie, and F. Guillemin, Estimating the prevalence and incidence of multiple sclerosis in the Lorraine region, France, by the capture-recapture method, Mult Scler, vol.18, issue.9, 2012.

M. Etemadifar, Z. Nasr, B. Khalili, M. Taherioun, and R. Vosoughi, Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis, Mult Scler Int, p.174720, 2015.

, Surveillance Atlas of Infectious Diseases, European Commission, 2018.

, Summary of Product Characteristics Engerix B, GUIDELINE ON THE USE OF STATISTICAL SIGNAL DETECTION METHODS IN THE EUDRAVIGILANCE DATA ANALYSIS SYSTEM, 2000.

, Guideline on good pharmacovigilance practices (GVP) Product-or Population-Specific Considerations I: Vaccines for prophylaxis against, European Medicine Agency, 2013.

, Pharmacovigilance Risk Assessment Committee (PRAC) -Accessed online on 13, 2017.

, ENCePP Guide on Methodological Standards in Pharmacoepidemiology

S. J. Evans, Stratification for spontaneous report databases, Drug Saf, issue.11, pp.1049-1052, 2008.

S. J. Evans, P. C. Waller, and S. Davis, Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports, Pharmacoepidemiol Drug Saf, vol.10, issue.6, pp.483-486, 2001.

M. F. Farez and J. Correale, Immunizations and risk of multiple sclerosis: systematic review and meta-analysis, Journal of neurology, vol.258, issue.7, pp.1197-1206, 2011.

C. P. Farrington, Relative incidence estimation from case series for vaccine safety evaluation, Biometrics, vol.51, issue.1, pp.228-235, 1995.

C. P. Farrington, H. J. Whitaker, and M. N. Hocine, Case series analysis for censored, perturbed, or curtailed post-event exposures, Biostatistics, vol.10, issue.1, pp.3-16, 2009.

E. Faure, Multiple sclerosis and hepatitis B vaccination: could minute contamination of the vaccine by partial hepatitis B virus polymerase play a role through molecular mimicry? Med Hypotheses, vol.65, pp.509-520, 2005.

P. Fine, K. Eames, and D. L. Heymann, Herd immunity": a rough guide, Clin Infect Dis, vol.52, issue.7, pp.911-916, 2011.

A. Flahault, H. Dreau, N. Farran, F. Carrat, P. Chauvin et al., Épidémiologie des maladies transmissibles en médecine générale-Bilan du réseau «Sentinelles» en 1996, Bull Epidemiol Hebd, vol.33, pp.149-151, 1997.

S. Foulon, G. Maura, M. Dalichampt, F. Alla, M. Debouverie et al., Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data, J Neurol, vol.264, issue.6, pp.1185-1192, 2017.

A. Fourrier, B. Bégaud, A. Alpérovitch, M. H. Verdier-taillefer, E. Touzé et al., Hepatitis B vaccine and first episodes of central nervous system demyelinating disorders: a comparison between reported and expected number of cases, British journal of clinical pharmacology, vol.51, issue.5, pp.489-490, 2001.

A. Fromont, C. Binquet, E. Sauleau, I. Fournel, R. Despalins et al.,

T. Moreau, National estimate of multiple sclerosis incidence in France, 2001.

, Multiple Sclerosis Journal, vol.18, issue.8, pp.1108-1115

D. A. Galloway, Papillomavirus vaccines in clinical trials, Lancet Infect Dis, vol.3, issue.8, pp.469-475, 2003.

J. Gee, A. Naleway, I. Shui, J. Baggs, R. Yin et al.,

M. F. Daley, Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink, Vaccine, vol.29, issue.46, pp.8279-8284, 2011.

D. A. Geier and M. R. Geier, A case-control study of serious autoimmune adverse events following hepatitis B immunization, Autoimmunity, vol.38, issue.4, pp.295-301, 2005.

D. A. Geier and M. R. Geier, A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events, Clin Rheumatol, vol.34, issue.7, pp.1225-1231, 2015.

D. A. Geier and M. R. Geier, Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database, Immunol Res, vol.65, issue.1, pp.46-54, 2017.

I. Gentile and G. Borgia, Vertical transmission of hepatitis B virus: challenges and solutions, Int J Womens Health, vol.6, pp.605-611, 2014.

E. Giacometti, La santé publique en otage, 2001.

. Gilberg-s, , 2011.

, Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS, Expert Rev Vaccines, vol.8, issue.6, pp.705-716, 2009.

K. B. Goetz, M. Pfleiderer, and C. K. Schneider, First-in-human clinical trials with vaccines--what regulators want, Nat Biotechnol, vol.28, issue.9, pp.910-916, 2010.

M. S. Gold, J. Buttery, and P. Mcintyre, Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance, Sex Health, vol.7, issue.3, pp.320-324, 2010.

S. T. Goldstein, F. Zhou, S. C. Hadler, B. P. Bell, E. E. Mast et al., A mathematical model to estimate global hepatitis B disease burden and vaccination impact, Int J Epidemiol, vol.34, issue.6, pp.1329-1339, 2005.

S. K. Greene, M. Rett, E. S. Weintraub, L. Li, R. Yin et al., Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, Am J Epidemiol, vol.175, issue.11, pp.1100-1109, 2009.

S. Greenland and A. Salvan, Bias in the one-step method for pooling study results, Statistics in medicine, vol.9, issue.3, pp.247-252, 1990.

L. Grimaldi-bensouda, D. Guillemot, B. Godeau, J. Benichou, C. Lebrun-frenay et al., Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects, Journal of Internal Medicine, vol.275, issue.4, pp.398-408, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01877831

L. Grimaldi-bensouda, M. Rossignol, I. Koné-paut, A. Krivitzky, C. Lebrun-frenay et al., Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance, J Autoimmun, Epub, pp.1-7, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01783748

G. Guyatt, A. D. Oxman, E. A. Akl, R. Kunz, G. Vist et al.,

R. Jaeschke, GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables, Journal of clinical epidemiology, vol.64, issue.4, pp.383-394, 2011.

K. Hammas, J. Yaouanq, M. Lannes, G. Edan, and J. F. Viel, Small-area distribution of multiple sclerosis incidence in western France: in search of environmental triggers, Int J Health Geogr, vol.16, issue.1, p.35, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01616063

S. Han, Clinical vaccine development, Clin Exp Vaccine Res, vol.4, issue.1, pp.46-53, 2015.

S. J. Hanley, E. Yoshioka, Y. Ito, and R. Kishi, HPV vaccination crisis in Japan, Lancet, vol.385, issue.9987, pp.61152-61159, 2015.

, COMMISSION DE LA TRANSPARENCE -Avis du 3 février, 2016.

L. Hazell and S. A. Shakir, Under-reporting of adverse drug reactions : a systematic review, Drug Saf, vol.29, issue.5, pp.385-396, 2006.

, Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP), MMWR Recomm Rep, vol.40, pp.1-25, 1991.

M. A. Hernan, S. S. Jick, M. J. Olek, and H. Jick, Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study, Neurology, vol.63, issue.5, pp.838-842, 2004.

L. Herroelen, J. De-keyser, and G. Ebinger, Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine, Lancet, vol.338, issue.8776, pp.1174-1175, 1991.

J. Higgins and S. G. Thompson, Quantifying heterogeneity in a meta-analysis, Statistics in medicine, vol.21, issue.11, pp.1539-1558, 2002.

J. P. Higgins and S. Green, Cochrane handbook for systematic reviews of interventions, vol.4, 2011.

M. N. Hocine, C. P. Farrington, E. Touze, H. J. Whitaker, A. Fourrier et al., Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method, Vaccine, vol.25, issue.31, pp.5938-5943, 2007.

J. Hopstadius, G. N. Noren, A. Bate, and I. R. Edwards, Impact of stratification on adverse drug reaction surveillance, Drug Saf, issue.11, pp.1035-1048, 2008.

L. Hostetler, Y. Hu, L. Tornes, and R. Lopez-alberola, Two cases of pediatric multiple sclerosis after human papillomavirus vaccination. Abstract #P088. Paper presented at the ACTRIMS Forum, IMI ADVANCE Group, vol.344, issue.23, p.1795, 2001.

C. Iniguez, J. A. Mauri, P. Larrode, J. Lopez-del-val, I. Jerico et al., Rev Neurol, issue.5, pp.430-432, 2000.

, Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders, Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders, 2002.

, Copyright 2002 by the National Academy of Sciences. All rights reserved

H. S. Izurieta, M. Wernecke, J. Kelman, S. Wong, R. Forshee et al., Effectiveness and Duration of Protection Provided by the Live-attenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older, Clin Infect Dis, vol.64, issue.6, pp.785-793, 2017.

S. J. Jacobsen, L. S. Sy, B. K. Ackerson, C. R. Chao, J. M. Slezak et al., An unmasking phenomenon in an observational post-licensure safety study of adolescent girls and young women, Vaccine, vol.30, issue.31, pp.4585-4587, 2012.

A. Jain, J. Marshall, A. Buikema, T. Bancroft, J. P. Kelly et al., Autism occurrence by MMR vaccine status among US children with older siblings with and without autism, Jama, issue.15, p.313, 2015.
DOI : 10.1097/ogx.0000000000000231

T. J. John and R. Samuel, Herd immunity and herd effect: new insights and definitions, Eur J Epidemiol, vol.16, issue.7, pp.601-606, 2000.

G. Kaplanski, F. Retornaz, J. Durand, and J. Soubeyrand, Central nervous system demyelination after vaccination against hepatitis B and HLA haplotype, J Neurol Neurosurg Psychiatry, vol.58, issue.6, pp.758-759, 1995.
DOI : 10.1136/jnnp.58.6.758-a
URL : https://jnnp.bmj.com/content/58/6/758.2.full.pdf

F. Karaali-savrun, A. Altintas, S. Saip, and A. Siva, Hepatitis B vaccine related-myelitis?, Eur J Neurol, vol.8, issue.6, pp.711-715, 2001.
DOI : 10.1046/j.1468-1331.2001.00290.x

D. Karussis, The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review, J Autoimmun, pp.134-142, 2014.

D. Karussis and P. Petrou, The spectrum of post-vaccination inflammatory CNS demyelinating syndromes, Autoimmun Rev, vol.13, issue.3, pp.215-224, 2014.

T. H. Kim, J. Johnstone, and M. Loeb, Vaccine herd effect, Scand J Infect Dis, vol.43, issue.9, pp.683-689, 2011.
DOI : 10.3109/00365548.2011.582247
URL : https://www.tandfonline.com/doi/pdf/10.3109/00365548.2011.582247?needAccess=true

E. Kinnunen, The incidence of optic neuritis and its prognosis for multiple sclerosis, Acta Neurol Scand, vol.68, issue.6, pp.371-377, 1983.

J. Labadie, Postlicensure safety evaluation of human papilloma virus vaccines. International journal of risk & safety in medicine, vol.23, pp.103-112, 2011.

A. Langer-gould, S. M. Brara, B. E. Beaber, and J. L. Zhang, Incidence of multiple sclerosis in multiple racial and ethnic groups, Neurology, vol.80, issue.19, pp.1734-1739, 2013.

A. Langer-gould, S. M. Brara, B. E. Beaber, and J. L. Zhang, The incidence of clinically isolated syndrome in a multi-ethnic cohort, Journal of neurology, vol.261, issue.7, pp.1349-1355, 2014.

A. Langer-gould, L. Qian, S. Y. Tartof, S. M. Brara, S. J. Jacobsen et al., Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases, JAMA neurology, vol.71, issue.12, pp.1506-1513, 2014.

H. J. Larson, A. De-figueiredo, Z. Xiahong, W. S. Schulz, P. Verger et al.,

N. S. Jones, The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey, EBioMedicine, vol.12, pp.295-301, 2016.

O. Launay and D. Floret, Sécurité et Efficacité de la vaccination Hépatite B en 2015 : Où en est-on?, La Revue du Praticien, vol.65, issue.7, pp.953-961, 2015.

R. Lavayssiere and A. E. Cabee, MRI in France: the French paradox, J Magn Reson Imaging, vol.13, issue.4, pp.528-533, 2001.

J. A. Leake, S. Albani, A. S. Kao, M. O. Senac, G. F. Billman et al.,

J. S. Bradley, Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features, Pediatr Infect Dis J, vol.23, issue.8, pp.756-764, 2004.

E. Leray, T. Moreau, A. Fromont, and G. Edan, Epidemiology of multiple sclerosis, Revue Neurologique, vol.172, issue.1, pp.3-13, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01255824

T. Lernout, G. Hendrickx, A. Vorsters, L. Mosina, N. Emiroglu et al., A cohesive European policy for hepatitis B vaccination, are we there yet?, Clin Microbiol Infect, issue.5, pp.19-24, 1920.

D. Lévy-bruhl, I. Rebière, J. Desenclos, and J. Drucker, Comparaison entre les risques de premières atteintes démyélinisantes centrales aigües et les bénéfices de la vaccination contre l'hépatite B, Bulletin Epidemiologique Hebdomadaire, vol.9, pp.1-8, 1999.

Z. Liu, T. Rashid, and A. G. Nyitray, Penises not required: a systematic review of the potential for human papillomavirus horizontal transmission that is non-sexual or does not include penile penetration, Sex Health, vol.13, issue.1, pp.10-21, 2016.

P. L. Lopalco, Spotlight on the 9-valent HPV vaccine, Drug Des Devel Ther, vol.11, pp.35-44, 2017.

S. Love, Demyelinating diseases, J Clin Pathol, vol.59, issue.11, pp.1151-1159, 2006.

F. D. Lublin, S. C. Reingold, J. A. Cohen, G. R. Cutter, P. S. Sorensen et al.,

C. H. Polman, Defining the clinical course of multiple sclerosis: the 2013 revisions, Neurology, vol.83, issue.3, pp.278-286, 2014.

J. H. Maclachlan and B. C. Cowie, Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med, vol.5, p.21410, 2015.

O. Mahaux, V. Bauchau, and L. Van-holle, Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines, Pharmacoepidemiol Drug Saf, vol.25, issue.2, pp.215-222, 2016.

M. T. Mailand and J. L. Frederiksen, Vaccines and multiple sclerosis: a systematic review, J Neurol, 2016.

D. O. Martin and H. Austin, An exact method for meta-analysis of case-control and follow-up studies, Epidemiology, vol.11, issue.3, pp.255-260, 2000.

V. Martínez-sernández and A. Figueiras, Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production, Journal of neurology, vol.260, issue.8, pp.1951-1959, 2013.

W. I. Mcdonald, A. Compston, G. Edan, D. Goodkin, H. P. Hartung et al.,

S. C. Reingold, Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Annals of neurology, vol.50, issue.1, pp.121-127, 2001.

J. Meerpohl, G. Langer, M. Perleth, G. Gartlehner, A. Kaminski-hartenthaler et al., GRADE guidelines: 3. Rating the quality of evidence (confidence in the estimates of effect), Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen, vol.106, issue.6, pp.449-456, 2011.

M. M. Mehndiratta and N. S. Gulati, Central and peripheral demyelination, J Neurosci Rural Pract, vol.5, issue.1, pp.84-86, 2014.

A. Miglietta, C. Quinten, P. L. Lopalco, and E. Duffell, Impact of hepatitis B vaccination on acute hepatitis B epidemiology in European Union/European Economic Area countries, Euro Surveill, issue.6, p.23, 2006.

Y. Mikaeloff, G. Caridade, M. Rossier, S. Suissa, and M. Tardieu, Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. Archives of pediatrics & adolescent medicine, vol.161, pp.1176-1182, 2007.

Y. Mikaeloff, G. Caridade, S. Suissa, and M. Tardieu, Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood, Neurology, vol.72, issue.10, pp.873-880, 2009.

D. Miller, F. Barkhof, X. Montalban, A. Thompson, and M. Filippi, Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis, Lancet Neurol, vol.4, issue.5, pp.70071-70076, 2005.

S. Ministère-des, L. De, and . Santé, Calendrier des vaccinations et recommandations vaccinales 2018, 2018.

S. Ministère-des, L. De, and . Santé, Vaccins obligatoires, questions-réponses, 2018.

S. Miranda, C. Chaignot, C. Collin, R. Dray-spira, A. Weill et al., Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France, Vaccine, vol.35, issue.36, pp.4761-4768, 2017.

D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and P. Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS med, vol.6, issue.7, p.1000097, 2009.

T. Moreau, E. Manceau, B. Lucas, M. Lemesle, R. Urbinelli et al., Incidence of multiple sclerosis in Dijon, France: a population-based ascertainment, Neurol Res, vol.22, issue.2, pp.156-159, 2000.

Y. Moride, F. Haramburu, A. A. Requejo, and B. Begaud, Under-reporting of adverse drug reactions in general practice, Br J Clin Pharmacol, vol.43, issue.2, pp.177-181, 1997.

J. Mouchet and B. Begaud, Central Demyelinating Diseases after Vaccination Against Hepatitis B Virus: A Disproportionality Analysis within the VAERS Database, Drug Saf, 2018.

J. Mouchet and B. Begaud, Central Demyelinating Diseases after Vaccination Against Hepatitis B Virus: A Disproportionality Analysis within the VAERS Database, Drug Saf, issue.8, pp.767-774, 2018.

J. Mouchet, F. Salvo, E. Raschi, E. Poluzzi, I. C. Antonazzo et al., Hepatitis B vaccination and the putative risk of central demyelinating diseases -A systematic review and meta-analysis, Vaccine, vol.36, issue.12, pp.1548-1555, 2018.

J. Mouchet, F. Salvo, E. Raschi, E. Poluzzi, I. C. Antonazzo et al., Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis, Pharmacol Res, vol.132, pp.108-118, 2018.

J. Mouchet and B. Bégaud, Hepatitis B Vaccination and Central DemyelinationHistory, description and observed/expected analyses of 624 cases reported to the French pharmacovigilance over a 20-year period, 2018.

, National Centre for immunisation research and surveillance (NCIRS), Multiple Sclerosis International Federation (MSIF), 2013.

E. Nicand, Le poids épidémiologique des hépatites virales B et C en France, 2016.

, Observatoire Français de la Sclérose en Plaque, 2016.

R. P. Ojha, B. E. Jackson, J. E. Tota, T. N. Offutt-powell, K. P. Singh et al., , 2014.

, Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States, Human vaccines & immunotherapeutics, vol.10, issue.1, pp.232-237

J. Ott, G. Stevens, J. Groeger, and S. Wiersma, Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity, Vaccine, vol.30, issue.12, pp.2212-2219, 2012.

J. Ott, A. Ullrich, M. Mascarenhas, and G. Stevens, Global cancer incidence and mortality caused by behavior and infection, Journal of Public Health, vol.33, issue.2, pp.223-233, 2010.

P. Pellegrino, C. Carnovale, V. Perrone, M. Pozzi, S. Antoniazzi et al., Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems, PLoS One, vol.8, issue.10, p.77766, 2013.

P. Pellegrino, C. Carnovale, M. Pozzi, S. Antoniazzi, V. Perrone et al.,

S. Radice, On the relationship between human papilloma virus vaccine and autoimmune diseases, Autoimmunity reviews, vol.13, issue.7, pp.736-741, 2014.

T. Petigara and D. Zhang, Pneumococcal Vaccine Coverage in Adults Aged 19-64 Years, Newly Diagnosed With Chronic Conditions in the U.S, Am J Prev Med, vol.54, issue.5, pp.630-636, 2018.

J. Peto, C. Gilham, J. Deacon, C. Taylor, C. Evans et al., Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort, British journal of cancer, vol.91, issue.5, pp.942-953, 2004.

S. Plotkin, History of vaccination, Proc Natl Acad Sci U S A, vol.111, issue.34, pp.12283-12287, 2014.

C. H. Polman, S. C. Reingold, B. Banwell, M. Clanet, J. A. Cohen et al.,

L. Kappos, Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Annals of neurology, vol.69, issue.2, pp.292-302, 2011.

C. H. Polman, S. C. Reingold, G. Edan, M. Filippi, H. P. Hartung et al., Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria, Annals of neurology, vol.58, issue.6, pp.840-846, 2005.

C. M. Poser, D. W. Paty, L. Scheinberg, W. I. Mcdonald, F. A. Davis et al.,

W. W. Tourtellotte, New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Annals of neurology, vol.13, issue.3, pp.227-231, 1983.

N. Previsani, D. Lavanchy, . Geneva, J. A. Queenan, T. Williamson et al., Representativeness of patients and providers in the Canadian Primary Care Sentinel Surveillance Network: a cross-sectional study, CMAJ Open, vol.4, issue.1, 2002.

S. V. Ramagopalan, W. Valdar, D. A. Dyment, G. C. Deluca, I. M. Yee et al.,

G. Canadian-collaborative-study, Association of infectious mononucleosis with multiple sclerosis. A population-based study, Neuroepidemiology, vol.32, issue.4, pp.257-262, 2009.

J. Renard, J. Guillamo, J. Ramirez, H. Taillia, D. Felten et al., , 1999.

, Presse Med, vol.28, issue.24, pp.1290-1292

D. Riethmuller, J. Prétet, F. Denis, F. Aubin, P. Pradat et al.,

C. Mougin, , 2009.

, Modélisation de l'impact de la vaccination HPV quadrivalente en France, Journal de Gynécologie Obstétrique et Biologie de la Reproduction, vol.38, issue.5, pp.389-395

O. T. Rutschmann, D. C. Mccrory, and D. B. Matchar, Immunization and MS A summary of published evidence and recommendations, Neurology, vol.59, issue.12, pp.1837-1843, 2002.

P. Saddier, , p.25, 2016.

A. D. Sadovnick and D. W. Scheifele, School-based hepatitis B vaccination programme and adolescent multiple sclerosis, The Lancet, vol.355, issue.9203, pp.549-550, 2000.

C. Sagnes-raffy, P. Gourraud, V. Hannon, R. Bourrel, M. Laffontan et al.,

M. Clanet, Multiple sclerosis in Haute-Garonne: an important underestimation of case numbers. Revue d'epidemiologie et de sante publique, vol.58, pp.23-31, 2010.

A. Saitoh and O. N. , Recent progress and concerns regarding the Japanese immunization program: addressing the "vaccine gap, vol.32, pp.4253-4261, 2014.

D. Santos-garcia, S. Arias-rivas, D. Dapena, and M. Arias, , 2007.

, Neurologia, vol.22, issue.8, pp.542-546

C. Sauvage, V. Féron, and C. Vincelet, Vaccination des Franciliens, 2010.

V. Schaffer, S. Wimmer, I. Rotaru, R. Topakian, H. P. Haring et al., HPV vaccine: a cornerstone of female health a possible cause of ADEM?, J Neurol, vol.255, issue.11, 2008.

N. M. Scheller, H. Svanström, B. Pasternak, L. Arnheim-dahlström, K. Sundström et al., Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system, Jama, vol.313, issue.1, pp.54-61, 2015.

G. Schumacker, G. Beebe, R. Kibler, L. Kurland, J. Kurtzke et al., Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis, Ann NY Acad Sci, vol.122, issue.6, pp.552-68, 1965.

A. Schweitzer, J. Horn, R. T. Mikolajczyk, G. Krause, and J. J. Ott, Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013, The Lancet, vol.386, p.61412, 2015.

S. Seabroke, G. Candore, K. Juhlin, N. Quarcoo, A. Wisniewski et al.,

J. Slattery, Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases, Drug Saf, vol.39, issue.4, pp.355-364, 2016.

K. Sekiguchi, N. Yasui, H. Kowa, F. Kanda, and T. Toda, Two Cases of Acute Disseminated Encephalomyelitis Following Vaccination Against Human Papilloma Virus, Intern Med, vol.55, issue.21, pp.3181-3184, 2016.

N. Shibata, S. Kimura, T. Hoshino, M. Takeuchi, and H. Urushihara, Effectiveness of influenza vaccination for children in Japan: Four-year observational study using a large-scale claims database, Vaccine, vol.36, issue.20, pp.2809-2815, 2018.

J. J. Shuster and M. A. Walker, Low-event-rate meta-analyses of clinical trials: implementing good practices, Statistics in medicine, 2016.

S. Sinsawaiwong and P. Thampanitchawong, Guillain -Barre' syndrome following recombinant hepatitis B vaccine and literature review, J Med Assoc Thai, vol.83, issue.9, pp.1124-1126, 2000.

B. A. Slade, L. Leidel, C. Vellozzi, E. J. Woo, W. Hua et al.,

M. M. Braun, Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine, Jama, vol.302, issue.7, pp.750-757, 2009.

P. Smith, Concepts of herd protection and immunity, Procedia in Vaccinology, vol.2, pp.134-139, 2010.

N. Souayah, P. Michas-martin, A. Nasar, N. Krivitskaya, H. A. Yacoub et al., Guillain-Barré syndrome after Gardasil vaccination: data from vaccine adverse event reporting system, Vaccine, vol.29, issue.5, pp.886-889, 2006.

G. Sridhar, F. Tian, R. Forshee, M. Kulldorff, N. Selvam et al.,

H. S. Izurieta, Evaluation of optic neuritis following human papillomavirus vaccination, Hum Vaccin Immunother, pp.1-9, 2017.

. Statista, Number of magnetic resonance imaging (MRI) devices in France from, 2006.

J. Stowe, N. Andrews, C. Kosky, G. Dennis, S. Eriksson et al., Risk of Narcolepsy after AS03 Adjuvanted Pandemic A/H1N1 2009 Influenza Vaccine in Adults: A Case-Coverage Study in England, Sleep, vol.39, issue.5, pp.1051-1057, 2016.

D. F. Stroup, J. A. Berlin, S. C. Morton, I. Olkin, G. D. Williamson et al.,

S. B. Thacker, Meta-analysis of observational studies in epidemiology: a proposal for reporting, Jama, vol.283, issue.15, pp.2008-2012, 2000.

M. Sturkenboom, L. Abenhaim, C. Wolfson, E. Roullet, O. Heinzlef et al., , 1999.

, Vaccinations, demyelination and multiple sclerosis study (VDAMS): a populationbased study in the UK, Pharmacoepidemiol Drug Saf, vol.8, issue.2, pp.170-171

S. Suissa, The case-time-control design, Epidemiology, vol.6, issue.3, pp.248-253, 1995.

I. Sutton, R. Lahoria, I. Tan, P. Clouston, and M. Barnett, CNS demyelination and quadrivalent HPV vaccination, Mult Scler, vol.15, issue.1, pp.116-119, 2009.

M. Sweeting, A. Sutton, and P. Lambert, What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data, Stat Med, vol.23, issue.9, pp.1351-1375, 2004.

D. Terney, S. Beniczky, P. Barsi, I. Kondakor, J. Perenyi et al.,

L. Vecsei, Multiple sclerosis after hepatitis B vaccination in a 16-year-old patient, Chin Med J (Engl), vol.119, issue.1, pp.77-79, 2006.

, Retrieved from https://www.historyofvaccines.org/content/first-laboratory-vaccine The College of Physicians of Philadelphia, Health Protection Report: Mumps increase in university students, 2009.

A. J. Thompson, B. L. Banwell, F. Barkhof, W. M. Carroll, T. Coetzee et al.,

J. A. Cohen, Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol, vol.17, issue.2, pp.162-173, 2018.

J. I. Tokars, P. Lewis, F. Destefano, M. Wise, M. Viray et al.,

C. Vellozzi, The risk of Guillain-Barre syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009-2010 seasonal influenza vaccines: results from selfcontrolled analyses, Pharmacoepidemiol Drug Saf, vol.21, issue.5, pp.546-552, 2012.

E. Touze, A. Fourrier, C. Rue-fenouche, E. Cile, V. Ronde-oustau et al.,

A. Alpérovitch, Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study, Neuroepidemiology, vol.21, issue.4, pp.180-186, 2002.

E. Touze, O. Gout, M. H. Verdier-taillefer, O. Lyon-caen, and A. Alperovitch, First central nervous system demyelination and hepatitis B vaccination: A pilot case control study, Revue Neurologique, vol.156, issue.3, pp.242-246, 2000.

B. K. Tsang and R. Macdonell, Multiple sclerosis-diagnosis, management and prognosis, Aust Fam Physician, vol.40, issue.12, pp.948-955, 2011.

P. G. Tuohy, Guillain-Barre syndrome following immunisation with synthetic hepatitis B vaccine, N Z Med J, vol.102, issue.863, pp.114-115, 1989.

S. Ludwig, I. S. Van-der-zee, R. Van-eden, W. Broere, and F. , Bystander activation of irrelevant CD4+ T cells following antigen-specific vaccination occurs in the presence and absence of adjuvant, PLoS One, vol.12, issue.5, 2015.

P. Van-damme, M. Cramm, J. C. Van-der-auwera, R. Vranckx, and A. Meheus, Horizontal transmission of hepatitis B virus, Lancet, vol.345, issue.8941, pp.27-29, 1995.

A. Veroniki, D. Jackson, W. Viechtbauer, R. Bender, J. Bowden et al., Methods to estimate the between-study variance and its uncertainty in metaanalysis, Res Synth Methods, vol.7, issue.1, pp.55-79, 2016.

T. Verstraeten, D. Descamps, M. David, T. Zahaf, K. Hardt et al.,

T. Breuer, Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines, Vaccine, vol.26, issue.51, pp.6630-6638, 2008.

M. Vichnin, P. Bonanni, N. P. Klein, S. M. Garland, S. L. Block et al.,

B. J. Kuter, An Overview of Quadrivalent Human Papillomavirus Vaccine Safety, Pediatr Infect Dis J, vol.34, issue.9, pp.983-991, 2006.

P. Waller, E. Van-puijenbroek, A. Egberts, and S. Evans, The reporting odds ratio versus the proportional reporting ratio: 'deuce', Pharmacoepidemiol Drug Saf, vol.13, issue.8, pp.525-526, 2004.

G. Wells, B. Shea, D. O'connell, J. Peterson, V. Welch et al., The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses Ottawa Health Research Institute (OHRI), 2006.

M. Welsch, N. Decker, J. ;. Imbs, . Demyelinisations, S. Systeme-nerveux et al., Tutorial in biostatistics: the self-controlled case series method, Stat Med, vol.25, issue.10, pp.1768-1797, 2006.

H. J. Whitaker, Y. Ghebremichael-weldeselassie, I. J. Douglas, L. Smeeth, and C. P. Farrington, Investigating the assumptions of the self-controlled case series method, Stat Med, vol.37, issue.4, pp.643-658, 2018.

H. J. Whitaker, M. N. Hocine, and C. P. Farrington, The methodology of self-controlled case series studies, Stat Methods Med Res, vol.18, issue.1, pp.7-26, 2009.

H. Wilhelm and M. Schabet, The Diagnosis and Treatment of Optic Neuritis, Dtsch Arztebl Int, vol.112, issue.37, pp.616-625, 2015.

C. Willame, D. Rosillon, J. Zima, M. G. Angelo, A. L. Stuurman et al.,

L. Baril, Risk of new onset autoimmune disease in 9-to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom, Hum Vaccin Immunother, vol.12, issue.11, pp.2862-2871, 2016.

S. E. Wilson, S. Quach, S. E. Macdonald, M. Naus, S. L. Deeks et al., Immunization information systems in Canada: Attributes, functionality, strengths and challenges. A Canadian Immunization Research Network study, Can J Public Health, vol.107, issue.6, 2017.
DOI : 10.17269/cjph.107.5679

E. J. Woo, R. Ball, D. R. Burwen, and M. M. Braun, Effects of stratification on data mining in the US Vaccine Adverse Event Reporting System (VAERS), Drug Saf, issue.8, pp.667-674, 2008.

, pdf;jsessionid=83D8424050B9BA1E4F6D7A59529D250F?sequence=1. World Health Organization, The European Health report 2005: Public health action for healthier children and populations, 2001.

, pdf;js essionid=F826C29D203C07B5C8B8503E8CCE0250?sequence=1 World Health Organization, WHO Technical Report, Guidelines on Clinical Evaluation of Vaccines: Regulatory Expectations. Annex 9, 2008.

, European health report, World Health Organization, 2018.

V. R. Patel, R. V. Goldenberg, and G. , Retrieved from http://vaccine-safetytraining.org/Importance-of-immunization-programmes.html Yanofsky, World Health Organization, vol.5, issue.6, pp.25-36, 2012.

J. Yaouanq, I. Tron, A. Kerbrat, E. Leray, S. Hamonic et al.,

G. Edan, Register-based incidence of multiple sclerosis in Brittany (north-western France, Acta Neurol Scand, vol.131, issue.5, pp.321-328, 2000.
URL : https://hal.archives-ouvertes.fr/inserm-01103109

J. Young, S. Quinn, M. Hurrell, and B. Taylor, Clinically isolated acute transverse myelitis: prognostic features and incidence, Mult Scler, vol.15, issue.11, pp.1295-1302, 2009.
DOI : 10.1177/1352458509345906

S. Yusuf, R. Peto, J. Lewis, R. Collins, and P. Sleight, Beta blockade during and after myocardial infarction: an overview of the randomized trials, Progress in cardiovascular diseases, vol.27, issue.5, pp.335-371, 1985.

Y. Zheng, Y. Lu, Q. Ye, Y. Xia, Y. Zhou et al., Should chronic hepatitis B mothers breastfeed? a meta analysis, BMC Public Health, vol.11, p.502, 2011.
DOI : 10.1186/1471-2458-11-502
URL : https://bmcpublichealth.biomedcentral.com/track/pdf/10.1186/1471-2458-11-502

F. Zipp, J. G. Weil, and K. M. Einhäupl, No increase in demyelinating diseases after hepatitis B vaccination, Nature medicine, vol.5, issue.9, pp.964-965, 1999.
DOI : 10.1038/12376

I. Zorych, D. Madigan, P. Ryan, and A. Bate, Disproportionality methods for pharmacovigilance in longitudinal observational databases, Stat Methods Med Res, vol.22, issue.1, pp.39-56, 2013.
DOI : 10.1177/0962280211403602

A. J. Zuckerman, Hepatitis vaccine: a note of caution, Nature, vol.255, issue.5504, p.104, 1975.

J. Mouchet and B. Bégaud, Central Demyelinating Diseases after Vaccination Against Hepatitis B Virus: A Disproportionality Analysis within the VAERS Database, Drug Saf, vol.41, issue.8, pp.767-774, 2018.
DOI : 10.1007/s40264-018-0652-4
URL : http://link.springer.com/10.1007/s40264-018-0652-4